Monopar Therapeutics Inc. (MNPR) is a late-stage biotherapeutics company engaged in the development of exclusive therapeutics used to extend the life span of cancer patients. The company’s product pipeline includes consists of Validive for the reduction of -induced oral mucositis induced by chemoradiotherapy in oropharyngeal cancer patients. Camsirubicin is another candidate for treating advanced soft tissue sarcoma, MNPR-101, and MNPR-202 for different cancer types and COVID-19.
The price of MNPR stock during the regular trading on February 17, 2022, was $2.98 with a gain of 2.52%. At last check in the premarket on February 18, 2022, the stock rocketed by 20.6%.
MNPR: Events and Happenings
On February 15, 2022, MNPR updated about its pipeline projects and expected 2022 highlights. Some of the key updates are mentioned below.
- Validive Phase 2/3 VOICE clinical studies is actively recruiting.
- Camsirubicin Phase 1 dose-escalation trial is actively Recruiting.
On January 07, 2022, MNPR reported its Executive management’s participation at the H.C. Wainwright BioConnect Conference on January 10, 2022. On December 08, 2021, MNPR announced optimistic recommendations regarding camsirubicin from the safety review committee. The committee recommended stepping up to the second dose stage in its Phase 1 trials. The committee reviewed the safety data in the initial dose cohort.
MNPR: Key Financials
On November 12, 2021, MNPR released its financial results for the third fiscal quarter 2021 ended September 30, 2021. Some of the key highlights are mentioned below.
EPS
Basic and diluted net loss per share in Q3 2021 was $2.45 million or $0.20 against $1.63 million or $0.15 in the same period of 2020. The EPS of the company decreased over the yearly period. The company beat the analysts’ estimated EPS by $0.01.
On October 27, 2021, MNPR informed the dosage of preliminary patients in Phase 1b clinical trials of camsirubicin.
Conclusion
MNPR stock is 38% down the six months and 64% down the past year. The recent premarket stock soaring is because of uncertain factors as the company did not report any SEC filing, official news, or recent event in the company’s calendar. Meanwhile, the analysts estimated the fourth quarter’s EPS to be in the range of -$0.19.
